S Cursiefen
Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
Tettenborn B, Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Maschke M, Limmroth V. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17 (1):31-7.
07.06.2010Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
07.06.2010Eur J Neurol 2010; 17 (1):31-7
Tettenborn Barbara, Putzki Norman, Yaldizli Oezguer, Mäurer M, Cursiefen S, Kuckert S, Maschke M, Limmroth V
Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. European journal of neurology : the official journal of the European Federation of Neurological Societies 2009
09.07.2009Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
09.07.2009European journal of neurology : the official journal of the European Federation of Neurological Societies 2009
Putzki Norman, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn Barbara, Limmroth V